| Prev Close | 62.26 |
| Open | 62.63 |
| Day Low/High | 61.60 / 62.69 |
| 52 Wk Low/High | 46.48 / 62.35 |
| Volume | 2.51M |
Astrazeneca PLC Sponsored ADR (AZN)
61.77
0.49
0.79
NYSE
| Exchange | NYSE |
| P/E Ratio | 51.70 |
| Div & Yield | N.A. (N.A) |
It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon
Surviving the age of Amazon is all there is to retailers' earnings.
Geron Shares Rise on Fast Track Designation -- Biotech Movers
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
3 Small Biotech Stocks Insiders Are Buying
Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.
'Date' These Potential Biotech Winners
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
'Date' These Potential Biotech Winners
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
These Stocks Are Ready to Reverse Course
This week's bullish and bearish reversal patterns.
AstraZeneca Shares Sink on Lackluster Mystic Drug Results
AstraZeneca shares are tanking.
China Was Right to Walk Away From Failed U.S. Trade Talks
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
These 3 Small Biotechs Have a Healthy Shot
Several firms hiked price targets on Portola into the $70s this week.
Give These 3 Small Biotechs a Shot
Several firms hiked price targets on Portola into the $70s this week.
Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies
U.K. Prime Minister Theresa May says technology companies have to do more to combat hate speech.
Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again
Stocks end the session mixed after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Keep Trading AstraZeneca From the Long Side
The stock is headed toward a bullish golden cross.
Closing Bell: Blizzard Conditions Mute Trading Activity; AstraZeneca Jumps
Stocks declined on Tuesday as wild weather stifled activity and led to low volume.
Egalet Makes Friday's Biotech Mailbag
Why the name is sagging, and what it will take to spur the sector higher.
Cramer: Don't Give the Fed Credit
Most of the 10 best stocks of the bull market did it their way.
Wake Up Wall Street: Donald Trump to Address Congress
U.S. stock futures and shares in Europe and Asia trade mixed Tuesday ahead of Donald Trump's first speech to a joint session of Congress.
Global Financial News: Nikkei 225 Snaps Losing Streak
Markets in Asia attempted to bridge the gap between U.S. and European markets overnight before paring gains as the session wound to a close
AstraZeneca Has Started a Turnaround
The old saying that volume precedes price could be playing out
Cramer: Money's Being Thrown at Almost Everything in the Market
There are nearly too many surging sectors to count.
Biotech Buoyed by Deal Talk
M&A activity is in a serious upswing, and here are some names to watch.
Cramer: Allergan Is the New Pharma Growth Stock
Jim Cramer compares Allergan's growth to other pharma stocks.
AstraZeneca Provides Cautious 2017 Guidance
AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.
News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach
Here is a round-up of the headlines from Europe.
Bullish and Bearish Reversals in the Market
These companies show signs of a change of direction.
Alexion Fires CEO, CFO in the Midst of Investigation on Improper Sales Practices
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
AstraZeneca Reports Positive Lung Cancer Drug Trial Results
AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.
